The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Development of HPMA copolymer–anticancer conjugates: Clinical experience and lessons learnt
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
The dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269
Self-citationPolymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1958 · Cited by 1,962
Self-citationDe Duve, C., De Barsy, T., Poole, B., Trouet, A., Tulkens, P., & Van Hoof, F. (1974) · Biochemical Pharmacology · doi:10.1016/0006-2952(74)90174-9 · Cited by 1,901
Structure and properties of pharmacologically active polymers
Ringsdorf, H. (1975) · Journal of Polymer Science: Polymer Symposia · doi:10.1002/polc.5070510111 · Cited by 1,094
Vasey, P. A., Kaye, S. B., Morrison, R. A., Twelves, C. J., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., et al. (1999) · PubMed · Cited by 689
Self-citationGreco, F., & Vicent, M. J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.05.006 · Cited by 652
HPMA copolymer–anticancer drug conjugates: design, activity, and mechanism of action
Kopecek, J. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00075-8 · Cited by 562
Dittmer, J. (2003) · Molecular Cancer · doi:10.1186/1476-4598-2-29 · Cited by 509
Cited by
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533
Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00346 · Cited by 3,070
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,730
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Fleige, E., Quadir, M. A., & Haag, R. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.01.020 · Cited by 1,111
Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects
Maeda, H. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100070g · Cited by 998
Nanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 981
Self-citationPolymer–drug conjugate therapeutics: advances, insights and prospects
Ekladious, I., Colson, Y. L., & Grinstaff, M. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0005-0 · Cited by 855
Polymeric Conjugates for Drug Delivery
Larson, N., & Ghandehari, H. (2012) · Chemistry of Materials · doi:10.1021/cm2031569 · Cited by 580
Mechanisms of drug release in nanotherapeutic delivery systems
Wong, P. T., & Choi, S. K. (2015) · Chemical Reviews · doi:10.1021/cr5004634 · Cited by 507
Receptor-targeted nanocarriers for therapeutic delivery to cancer
Yu, B., Tai, H. C., Xue, W., Lee, L. J., & Lee, R. J. (2010) · Molecular Membrane Biology · doi:10.3109/09687688.2010.521200 · Cited by 423
Paclitaxel: What has been done and the challenges remain ahead
Bernabeu, E., Cagel, M., Lagomarsino, E., Moretton, M., & Chiappetta, D. A. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.05.016 · Cited by 413
Polymer therapeutics-prospects for 21st century: The end of the beginning
Duncan, R., & Vicent, M. J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.012 · Cited by 412
Self-citationNanotheranostics and image-guided drug delivery: current concepts and future directions
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100228v · Cited by 397
Nanocarriers for delivery of platinum anticancer drugs
Oberoi, H. S., Nukolova, N. V., Kabanov, A. V., & Bronich, T. K. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.014 · Cited by 396
Prodrug-based nanoparticulate drug delivery strategies for cancer therapy
Luo, C., Sun, J., Sun, B., & He, Z. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.09.008 · Cited by 352
Stimuli-sensitive nanopreparations for combination cancer therapy
Jhaveri, A., Deshpande, P., & Torchilin, V. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.002 · Cited by 334
Duncan, R., & Richardson, S. C. W. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300293n · Cited by 332
Self-citationPoly(2‐Oxazoline)s – Are They More Advantageous for Biomedical Applications Than Other Polymers?
Sedlacek, O., Monnery, B. D., Filippov, S. K., Hoogenboom, R., & Hruby, M. (2012) · Macromolecular Rapid Communications · doi:10.1002/marc.201200453 · Cited by 312
Nanotechnology applied to overcome tumor drug resistance
Gao, Z., Zhang, L., & Sun, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.051 · Cited by 303
Kierstead, P. H., Okochi, H., Venditto, V. J., Chuong, T. C., Kivimae, S., Fréchet, J. M. J., & Szoka, F. C. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.06.023 · Cited by 210
Drug targeting to the diseased liver
Poelstra, K., Prakash, J., & Beljaars, L. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.02.011 · Cited by 172
“proteins, antiviral agents [12] to anticancer drugs [13–15] into hepatocytes.”
BackgroundKe, X., Ng, V. W. L., Ono, R. J., Chan, J. M. W., Krishnamurthy, S., Wang, Y., Hedrick, J. L., & Yang, Y. Y. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.061 · Cited by 146
Camacho, K. M., Kumar, S., Menegatti, S., Vogus, D. R., Anselmo, A. C., & Mitragotri, S. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.031 · Cited by 97
Hepatocyte targeting via the asialoglycoprotein receptor
Ramírez-Cortés, F., & Ménová, P. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00652f · Cited by 55
Nanoconjugate formulations for enhanced drug delivery
Oner, E., Ilhan, M., Gultekin, H. E., & Karpuz, M. (2023) · Advanced and Modern Approaches for Drug Delivery · doi:10.1016/b978-0-323-91668-4.00023-x · Cited by 4
Metadata
- Authors
- Duncan, R.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2009-11
- Volume
- 61
- Issue
- 13
- Pages
- 1131-1148
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2077405964
- Cited by
- 252
- References
- 74
- FWCI
- 0.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.